U.S. markets closed

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.1900-0.0600 (-2.67%)
At close: 04:00PM EDT
2.2000 +0.01 (+0.46%)
After hours: 07:36PM EDT
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
Currency in USD

Valuation Measures4

Yahoo Finance Plus required to access annual data
Yahoo Finance Plus required to access monthly data
Upgrade to begin using 40 years of financial statements and get so much more.
As of Date: 4/14/2024
Market Cap (intraday)
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (5 yr expected)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Trading Information

Stock Price History

Beta (5Y Monthly) 1.20
52-Week Change 3-37.18%
S&P500 52-Week Change 323.42%
52 Week High 34.3500
52 Week Low 30.7900
50-Day Moving Average 32.3070
200-Day Moving Average 31.8687

Share Statistics

Avg Vol (3 month) 3142.32k
Avg Vol (10 day) 337.84k
Shares Outstanding 56.57M
Implied Shares Outstanding 66.57M
Float 85.57M
% Held by Insiders 113.85%
% Held by Institutions 19.58%
Shares Short (Mar 28, 2024) 420.28k
Short Ratio (Mar 28, 2024) 40.38
Short % of Float (Mar 28, 2024) 40.36%
Short % of Shares Outstanding (Mar 28, 2024) 40.31%
Shares Short (prior month Feb 29, 2024) 451.34k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:6
Last Split Date 3Jun 30, 2023

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023


Profit Margin 0.00%
Operating Margin (ttm)-440,356,600.00%

Management Effectiveness

Return on Assets (ttm)-63.67%
Return on Equity (ttm)-118.88%

Income Statement

Revenue (ttm)260.5k
Revenue Per Share (ttm)0.05
Quarterly Revenue Growth (yoy)-100.00%
Gross Profit (ttm)N/A
EBITDA -19.91M
Net Income Avi to Common (ttm)-19.03M
Diluted EPS (ttm)-3.5700
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)13.25M
Total Cash Per Share (mrq)2.05
Total Debt (mrq)622k
Total Debt/Equity (mrq)5.67%
Current Ratio (mrq)4.13
Book Value Per Share (mrq)1.77

Cash Flow Statement

Operating Cash Flow (ttm)-18.09M
Levered Free Cash Flow (ttm)-12.17M